Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome

Table 2 Comparison between the failure and remission groups before tacrolimus induction

Characteristics	Remission (n = 30)	Failure (n = 17)	P value
Age (yr), mean ± SD	41.33 ± 16.8	51.1 ± 20.7	0.084
Male/female, n (%)	23/7 (76.7 / 23.3)	15/2 (88.2/11.8)	0.455
Disease duration (yr), mean ± SD	2.0 ± 2.8	5.46 ± 10.9	0.098
Disease extent, n (%)
Extensive colitis	27 (90.0)	15 (88.2)	1
Left sided colitis	3 (10.0)	2 (11.8)
CAI (Rachmilewitz index), mean ± SD	10.7 ± 2.4	11.7 ± 2.9	0.221
MES
MES 2	6 (20.0)	3 (17.6)	1
MES 3	24 (80.0)	14 (82.4)
Medication at study, n (%)
Oral 5-ASA	16 (53.3)	5 (29.4)	0.138
Suppository 5-ASA	5 (16.7)	2 (11.8)	1
Systemic steroids	19 (63.3)	9 (52.9)	0.546
Immunomodulators	6 (20.0)	4 (23.5)	1
Biologics	6 (20.0)	5 (29.4)	0.493
History of biologics, n (%)	6 (20.0)	6 (35.3)	0.306
Time to high trough level (d), mean ± SD	7.9 ± 8.1	8.5 ± 6.4	0.773

5-ASA: 5-aminosalicylic acid; CAI: Clinical activity index; MES: Mayo endoscopic subscore.